As med-tech startups look to raise capital without diluting the valuation of their company, many may look to sell ...

The draft Medicare physician fee schedule for calendar year 2025 provoked a strong backlash from physician societies due to a ...

In what represents its first patenting, Roseville, Minn.-based Iveacare Inc. provides insights as to what its first ...

Australia is the skin cancer capital of the world, but with a shortage of dermatologists, patients often wait too long to get ...

Researchers from Johnson & Johnson presented the discovery of a novel inhibitor of cyclin-dependent kinase 7 (CDK7), a ...

The specter of elevated liver enzymes, a known problem with the drug class, became a topic of talk with regard to Sanofi SA’s ...

DNA is open and accessible, while the action of an epigenetic editor turns it into functionally inactive DNA, which is closed ...

Following the recent recommendation of its advisory committee, the U.S. FDA gave the nod to Zevra Therapeutics Inc.’s ...

Rakuten Medical Inc. has presented preclinical results with RM-0256, a PD-L1-targeted photoimmunotherapy, showing its ability ...

Wall Street apparently wanted more from Prelude Therapeutics Inc.’s phase I data with SMARCA2 enzyme degrader PRT-3789 in ...

Cincera Therapeutics Pty Ltd. and Monash University co-presented the phenotypic drug discovery of CIN-244, a novel MRTF/SRF ...

Australia’s Health Department has released the final report of the Health Technology Assessment (HTA) Review that makes 50 ...